Crescendo Bioscience Announces the U.S. Launch of the First Multi-Biomarker Blood Test for Rheumatoid Arthritis Disease Activity
11/8/2010 10:32:22 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Crescendo Bioscience announced today the commercial launch of Vectra DA, its first-in-class multi-biomarker blood test designed to aid physicians in managing patients with rheumatoid arthritis (RA). Vectra DA analyzes 12 key serum biomarkers to produce a single objective score that quantifies RA disease activity. Launched today at the ACR/ARHP Annual Scientific Meeting , Vectra DA is now available to physicians in 47 states (laboratory licensure has been applied for in Maryland and Rhode Island and is planned for New York).